{"slideshow_credits": null, "snippet": "While the drug, crenezumab, did not slow progression of the disease over all, at the highest doses it seemed to delay a decline in mental ability in patients with mild Alzheimer\u2019s.", "abstract": "Roche reports mixed results in its latest trial of Alzheimer's drug crenezumab.", "section_name": "Business Day", "print_page": "4", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/07/17/business/roche-reports-mixed-results-in-trial-of-an-alzheimers-drug.html", "lead_paragraph": "While the drug, crenezumab, did not slow progression of the disease over all, at the highest doses it seemed to delay a decline in mental ability in patients with mild Alzheimer\u2019s.", "headline": {"main": "Roche Reports Mixed Results in Trial of an Alzheimer\u2019s Drug", "print_headline": "Mixed Results for Roche in Alzheimer\u2019s Drug Trial"}, "_id": "53c710b638f0d858f3e38852", "word_count": "743", "multimedia": [], "pub_date": "2014-07-17T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Alzheimer's Disease", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Roche Holding A G", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}